Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Steve E. Krognes Insider Profile
4 Followers
Steve E. Krognes, Director at Denali Therapeutics, holds 807.55K shares in Denali Therapeutics (Ticker: DNLI), holds ― shares in Corvus Pharmaceuticals (Ticker: CRVS), holds ― shares in Gritstone bio (Ticker: GRTSQ). Most recently, Steve E. Krognes Sold ― shares of Denali Therapeutics on Jan 08, 2025 for an estimated value of 69.48K.
Profitable Transactions
12 out of 16 Profitable Transactions
Average Return
+3.10%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Steve E. Krognes holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Feb 16, 2021 - Feb 16, 2022
Return:+44.30%
The most profitable trade made by Steve E. Krognes
Steve E. Krognes's Trading History
Denali Therapeutics
Jan 08, 2025
Director
Informative Sell
69.48K
$17.71M
Corvus Pharmaceuticals
―
Director
―
―
Gritstone bio
―
Director
―
―
Guardant Health
Jan 02, 2025
Director
Uninformative Buy
4.74K
$374.67K
Pliant Therapeutics
―
Director
―
―
List of latest transactions for each holding click on a transaction to see Steve E. Krognes's performance on stock
You May Also Like
Steve E. Krognes insider profile FAQ
What is the percentage of profitable transactions made by Steve E. Krognes?
The percentage of profitable transactions made by Steve E. Krognes is 75%.
What is the average return per transaction made by Steve E. Krognes?
The average return per transaction made by Steve E. Krognes is 3.10%.
What stocks does Steve E. Krognes hold?
Steve E. Krognes holds: DNLI, CRVS, GRTSQ, GH, PLRX stocks.
What was Steve E. Krognes’s latest transaction?
Steve E. Krognes latest transaction was an Informative Sell of $69.48K.
What was Steve E. Krognes's most profitable transaction?
Steve E. Krognes’s most profitable transaction was an Informative Sell of DNLI stock on February 16, 2021. The return on the trade was 44.30%.
What is Steve E. Krognes's role in Denali Therapeutics?
Steve E. Krognes's role in Denali Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.